← Back to 52-Week Low Lens

MTI LTD

1. Company Overview

MTI Ltd. is a Japanese software and digital services company that started as a mobile content subscription business and is now trying to become a healthcare and school-DX platform company. Its best-known assets are consumer content services such as music.jp and the AdGuard-related security offering, the Luna Luna women’s health service, pharmacy software centered on a cloud-based medication history system, municipal childcare DX services, and BLEND, a cloud-based school affairs platform.

Growth is being driven by two concrete engines. First, the pharmacy DX business: cloud medication-history installations rose from 2,528 stores at Sep. 2024 to 3,811 at Sep. 2025 and 4,166 at Dec. 2025. Second, school DX: BLEND installations rose from 541 schools in Apr. 2023 to 775 in Apr. 2024 and 1,067 in Apr. 2025.

Owner earnings need a sanity check because headline FY2025 profit was flattered. Reported FY2025 net income was JPY3.4bn. Total investing cash outflow was JPY1.7bn, mostly software. I estimate only JPY0.4-0.7bn of that was true sustaining capex; the rest appears tied to expansion in pharmacy DX, childcare DX, and related software. Working capital was roughly neutral over a cycle. After removing the roughly JPY0.8bn consumption-tax refund and unusually favorable tax items, recurring owner earnings look closer to JPY2.0-2.3bn. That implies an owner-earnings yield of roughly 6-7% on the current market cap. This is meaningfully worse than the headline P/E because FY2025 earnings were unusually high and some software spend is capitalized rather than expensed immediately.

Capital efficiency is mixed, not uniform. Reported ROE improved sharply from 5.4% in FY2023 to 16.1% in FY2024 and 20.1% in FY2025. Incremental capital in school DX appears to be earning high returns: segment revenue rose from JPY1.2bn in FY2024 to JPY1.9bn in FY2025, while segment profit swung from a JPY66m loss to a JPY550m profit. Healthcare is the opposite: revenue rose strongly, but profit slipped from JPY352m in FY2024 to a JPY80m loss in FY2025 because development spending increased. So incremental capital is working very well in school DX, but is not yet proven in healthcare.

Business quality is therefore uneven but not poor. The profits still come mainly from the legacy content business and the other B2B/DX bucket, not from healthcare. That matters. MTI is a transition story, not a finished SaaS compounder. The good parts of the business are recurring revenue, low marginal cost software, deep workflow integration in schools and pharmacies, and a very strong balance sheet. The weaker part is that the original consumer-content moat was always shallower than it looked, and much of that old economics is in secular decline.

2. How the Company Makes Money

MTI reports four segments: content, healthcare, school DX, and other. The content business still pays the bills. It includes entertainment and lifestyle subscriptions, security-related apps, and original comics. Healthcare includes Luna Luna, CARADA-related services, municipal childcare DX, and pharmacy software. School DX is mainly BLEND, a cloud-based school affairs system. Other includes AI and corporate DX support.

These segment profits are before corporate costs and eliminations, which were roughly JPY2.7bn in FY2025. The key point is simple: today’s consolidated profit still depends on content, while future growth depends on school DX and, if it ever matures properly, healthcare.

The content business has historically been a good business because subscription revenue is recurring, gross margins are high, and capital intensity is low. The newer healthcare and school DX businesses are attractive for a different reason: once a pharmacy, municipality, or school installs the software and trains staff on it, switching is inconvenient. That creates real switching costs, but only after installation. So MTI’s moat is not brand glamour or technology supremacy. It is a combination of installed-base friction, workflow fit, and relationships in slow-moving Japanese institutions.

3. Why the Stock Fell

The stock is near a 52-week low because the market stopped paying for the “transition to DX” story and started focusing on what current earnings really are. The shares fell from about JPY973 in July 2025 to about JPY618 at the end of March 2026, a drop of roughly 36%, and briefly touched JPY616.

The immediate reason is not a collapse in revenue. It is a collapse in perceived earnings quality. FY2025 net income was JPY3.4bn, but FY2026 guidance calls for only JPY1.77-2.05bn, down 40-48%. That looks bad on a screen. The problem is that FY2025 included special items, especially roughly JPY0.8bn of consumption-tax refund income and favorable tax effects. Meanwhile, healthcare, which is supposed to be a future pillar, swung from a JPY352m segment profit in FY2024 to a JPY80m loss in FY2025 despite strong sales growth. Investors are concluding that the “new MTI” is either less profitable than advertised or taking longer to become profitable.

The second source of anxiety is mix. Content is still the profit center, but it is structurally mature. School DX is growing quickly, but it already has about 50% share of private middle and high schools, so investors worry the easy part of that growth is over. The next leg is public schools, where sales cycles are slower and procurement is more political and lumpy.

4. What the Market Is Assuming

(a) One-time, cyclical, or sentiment-driven factors

• FY2025 earnings were flattered by one-off tax-related items.
• FY2026 net income guidance implies a sharp profit drop.
• Q1 FY2026 was fine, but management did not change the narrative enough to reset sentiment.

(b) Medium-term business headwinds

• Healthcare growth is being bought with development spending.
• School DX growth will be harder after strong private-school penetration.
• Content needs security-app and comics growth just to offset secular decay in older subscriptions.

(c) Potential long-term structural threats

• The old paid-content subscriber funnel is permanently weaker than it used to be.
• Healthcare and school software could face pricing pressure if larger vendors bundle adjacent products.
• MTI could spread capital across too many subscale initiatives instead of concentrating on winners.

MTI does not disclose ARR or churn in a way that lets an outside investor build a clean SaaS cohort model. Revenue, installation counts, margins, cash flow, and leverage are therefore the most useful operating facts available.

5. Temporary or Structural?

The market is reacting to a mix of TIME and ESSENCE. The earnings drop being shown on headline net income is mostly TIME. The legacy content business being structurally mature is ESSENCE. The real investment question is whether the newer DX businesses can replace the old cash engine before the old engine erodes too far.

So the core value-creation mechanism is not broken. What is broken is the old version of MTI: the idea that mobile content alone can be the long-term engine. That damage is real and irreversible. But the newer businesses are not showing demand failure. They are showing a transition in which one growth engine, school DX, is already proving itself, while the second, healthcare, is still expensive and unfinished.

6. Is the Market Wrong? By How Much?

Time-as-a-moat test. If I had MTI’s current market cap in cash, I could build competing software. What I could not do quickly is replicate its installed base and institutional relationships.

Within 2 years: No, not realistically. You could build a pharmacy product or a school product, but you would not replicate more than 4,000 pharmacy installs, more than 1,000 school references, municipal relationships, and workflow trust in two years. Procurement cycles alone would stop you.

Within 5 years: Partly. A capable competitor with JPY34bn could build a credible rival in one vertical. The real blockers would still be trust, integrations, sales channels, and switching friction after implementation.

Within 10 years: Yes, probably. This is not an impregnable moat. Over a decade, a determined competitor or larger software incumbent could replicate much of the product stack. What would still matter are customer references, data integrations, and reputation in regulated or slow-moving institutional settings.

Mispricing. At roughly JPY34.3bn of market value and about JPY16bn of net cash, the market is valuing the operating business at only about JPY18bn. Against normalized owner earnings of roughly JPY2.0-2.3bn, that is an 11-13% owner-earnings yield on the operating assets, or about 6-7% on the full equity. For a debt-light business still growing revenue and already proving that school DX can scale, that looks too pessimistic. For a business whose legacy moat has undeniably weakened, it is not outrageously cheap. My judgment is that the market is undervaluing MTI by roughly JPY6-10bn.

What the market is getting wrong: it is treating the FY2026 net-income drop as if the business itself were deteriorating, when the cleaner operating picture is still improving. It is also discounting too heavily the value of the net cash and the fact that school DX has crossed from investment phase to profit phase. What the market is getting right is that legacy content is a structurally weaker franchise than it once was, and healthcare still has something to prove.

7. Key Facts, Estimates, and Judgments

CoffeeAnd — 52-week low lens